Cat. No. | Product name | CAS No. |
DC24010 |
Plpro-IN-6(PLpro inhibitor)
Featured
A potent, noncovalent SARS-CoV papain-like protease (PLpro) inhibitor with IC50 of 2.6 uM. |
1093070-14-4 |
DC21979 |
ATF6 agonist compound A147
Featured
ATF6 agonist compound A147 is a specific, small molecule agonist of transcription factor ATF6, activates ATF6 and influences differentiation of stem cells.147 has broad antiviral activity against multiple DENV strains and serotypes and that the compound i |
393121-74-9 |
DCAPI1051 |
Arbidol HCl (Umifenovir)
Featured
Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational HIV therapies. Arbidol hydrochloride (Umifenovir hydroc |
131707-23-8 |
DC5064 |
Baricitinib (INCB28050, LY3009104)
Featured
Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2). |
1187594-09-7 |
DC8258 |
Baricitinib phosphate
Featured
Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2). |
1187595-84-1 |
DC21382 |
EIDD-1931(NHC)
Featured
EIDD-1931 (β-d-N4-Hydroxycytidine, NHC) inhibits both murine hepatitis virus (MHV) (EC50 of 0.17 μM) and Middle East respiratory syndrome CoV (MERS-CoV) (EC50 of 0.56 μM) with minimal cytotoxicity. It also inhibits SARS-CoV-2 and multiple 2 endemic, epide |
3258-02-4 |
DC5077 |
Boceprevir(EBP 520; SCH 503034 )
Featured
Boceprevir(EBP 520; SCH 503034 ) is useful for Anti HCV. |
394730-60-0 |
DC1002 |
Carfilzomib (PR-171)
Featured
Carfilzomib is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells,showed potent activity against COVID-19(SARS-COV-2). |
868540-17-4 |
DCAPI1085 |
Clevudine (Levovir)
Featured
Clevudine (Levovir) is an antiviral drug for the treatment of hepatitis B,showed potent activity against COVID-19(SARS-COV-2) . |
163252-36-6 |
DC8908 |
Darunavir ethanolate
Featured
Darunavir ethanolate is an HIV protease inhibitor,showed potent activity against COVID-19(SARS-COV-2). |
635728-49-3 |
DC8485 |
E-64d(Aloxistatin)
Featured
E-64D is an inhibitor of cathepsins B and L; also thought to inhibit calpain,showed a potent activity for COVID-19(SARS-COV-2)with EC50: MERS-COV(1.275),SARS-COV(0.760) |
88321-09-9 |
DC2107 |
Gemcitabine HCl (Gemzar,LY188011)
Featured
Gemcitabine Hydrochloride (Gemzar) is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively,showed potent activity against COVID-19(SARS-COV-2) with EC50 MERS-COV(1.216), SARS-COV(4.9 |
122111-03-9 |
DC22629 |
GRL-0617
Featured
GRL-0617 is a potent, noncovalent SARS-CoV papain-like protease (PLpro) inhibitor with IC50 of 0.6 uM, Ki of 0.49 uM. |
1093070-16-6 |
DCAPI1505 |
Darunavir
Featured
Darunavir(TMC114) is an HIV protease inhibitor,showed potent activity against COVID-19(SARS-COV-2) . |
206361-99-1 |
DC8983 |
Ibudilast
Featured
Ibudilast(KC-404;AV-411;MN-166) is a relatively nonselective phosphodiesterase inhibitor which has been marketed for treating asthma,ibudilast (MN-166) is tested to treat acute respiratory distress syndrome (ARDS) associated with Covid-19. |
50847-11-5 |
DC8907 |
Lopinavir
Featured
Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM,showed potent activity against COVID-19(SARS-COV-2). |
192725-17-0 |
DC12255 |
MLN-4760
Featured
MLN-4760 is a potent and selective human ACE2 inhibitor (IC50, 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM). |
305335-31-3 |
DC9619 |
Nafamostat (mesylate)
Featured
Nafamostat mesylate, a synthetic serine protease inhibitor, is an anticoagulant,showed highly potent activity against COVID-19(SARS-COV-2). |
82956-11-4 |
DC10355 |
Nelfinavir
Featured
Nelfinavir(AG-1341) is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki=2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection. |
159989-64-7 |
DC9474 |
Nelfinavir (Mesylate)
Nelfinavir(AG-1341) is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki=2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection. |
159989-65-8 |
DC23149 |
Oseltamivir acid
Oseltamivir acid (GS 4071, Ro 64-0802, Oseltamivir carboxylate) is a potent inhibitor of influenza neuraminidase (NA) with Ki of <1 nM for both A and B strains,showed potent activity against COVID-19(SARS-COV-2). |
187227-45-8 |
DCAPI1594 |
Oseltamivir phosphate
Featured
OSELTAMIVIR is an active (orally) inhibitor of the influenze virus neuraminidase and converted to the active acid metabolite in vivo. |
204255-11-8 |
DC7992 |
PX 12
Featured
PX-12(IV-2) is an irreversible inhibitor of Thioredoxin-1(Trx-1) currently in clinical development as an antitumor agent; IC50=7 uM in Hela, MTT assay, 72 h. |
141400-58-0 |
DCAPI1165 |
Ribavirin (Copegus)
Featured
Ribavirin is a guanosine analog with antiviral properties against DNA and RNA viruses, including respiratory syncytial virus, hepatitis C, and influenza. |
36791-04-5 |
DC9475 |
Ritonavir
Featured
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS,showed potent activity against COVID-19(SARS-COV-2) . |
155213-67-5 |
DC5105 |
Favipiravir (T-705)
Featured
T 705(Favipiravir) is a RNA-directed RNA polymerase NS5B inhibitor.T 705(Favipiravir) is useful for Antiviral agents. |
259793-96-9 |
DC9180 |
Tamoxifen Citrate
Featured
Tamoxifen(ICI-46474) is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen,showed potent activity against COVID-19(SARS-COV-2) with EC50 MERS-COV(10.117), SARS-COV(11.696). |
54965-24-1 |
DC2067 |
TDZD-8
Featured
TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM. |
327036-89-5 |
DC1008 |
Telaprevir (VX-950)
Featured
Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM. |
402957-28-2 |
DC21567 |
Triazavirin (Riamilovir)
Featured
Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain. It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications.5 Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19. |
928659-17-0 |
DCAPI1063 |
Zanamivir (Relenza)
Featured
Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively. |
139110-80-8 |
DC10325 |
Aviptadil
Featured
Aviptadil (INN) is an analog of vasoactive intestinal polypeptide (VIP) for the treatment of erectile dysfunction,showed potent activity against COVID-19(SARS-COV-2). |
40077-57-4 |
DC26121 |
FOY-251 mesylate
Featured
FOY 251 is a metabolite of Camostat and a pollen protease inhibitor for prevention and control of allergy. |
71079-09-9 |
DC26133 |
Camostat mesylate
Featured
Camostat mesylate is a synthetic, orally bioavailable is a serine protease inhibitor. Used for the treatment of chronic pancreatitis. It attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. |
59721-29-8 |
DC11735 |
Remdesivir(GS-5734)
Featured
Remdesivir is a novel RNA-dependent RNA Polymerase,(RdRp) inhibitor. The purity of remdesivir>99.8%,signal impurity<0.05%. |
1809249-37-3 |
DC26208 |
Remdesivir metabolite(GS-441524)
Featured
Remdesivir metabolite.Remdesivir blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 Nm,and also showed potent activity blocking 2019-nCov(Coronavirus). |
1191237-69-0 |
DC26230 |
Furin Inhibitor I
Featured
Furin inhibitor I is a selective, irreversible, and cell-permeable competitive inhibitor of proprotein convertases, including furin/SPC1 (Ki = ~1 nM), SPC2/PC2 (Ki = 0.36 nM), SPC3/PC1/PC3 (Ki = 2.0 nM), SPC4/PACE4 (Ki = 3.6 nM), SPC6/PC5/PC6, and SPC7/LP |
150113-99-8 |
DC26232 |
DX 600(ACE2 Inhibitor)
Featured
DX600 is a potent and selective peptide inhibitor of angiotensin-converting enzyme 2 (ACE2; Kis = 2.8, 200, and 1,200 nM for recombinant, human, and murine ACE2, respectively). |
478188-26-0 |
DC26231 |
Furin Inhibitor II(Hexa-D-arginine)
Featured
Inhibitor of furin (Ki values are 0.106, 0.58 and 13.2 μM for furin, PACE4 and PC1 respectively). |
673202-67-0 |
DC27020 |
Arbidol analog
Featured
A Arbidol analog which showed affinity against both H3 (1150-fold) and H1 (98-fold) hemagglutinin subtypes than Arbidol. |
2126032-35-5 |
DC27035 |
EIDD-2801(Molnupiravir)
Featured
Molnupiravir, also known as EIDD-2801 and MK-4482, is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. EIDD-2801 has been show |
2492423-29-5 |
DC28010 |
Carolacton
Carolacton is a novel MTHFD1 inhibitor,an antibacterial compound,also showed potent activity against COVID-19(SARS-COV-2). |
476645-77-9 |
DC28040 |
SBP1(spike-binding peptide 1)
Featured
SBP1(spike-binding peptide 1) is a first-in-class peptide binder to the SARS-CoV-2 spike protein. SBP1 specifically binds SARS-CoV-2-RBD with low nanomolar affinity. SBP1 to the RBD was determined to be 47 nM with the average Kon = 4.69*104M-1S-1 and Koff |
|
DC28041 |
BIOTIN-PEG4-SBP1(spike-binding peptide 1)
Featured
Biotin modification of SBP1.SBP1(spike-binding peptide 1) is a first-in-class peptide binder to the SARS-CoV-2 spike protein. SBP1 specifically binds SARS-CoV-2-RBD with low nanomolar affinity. SBP1 to the RBD was determined to be 47 nM with the average Kon = 4.69*104M-1S-1 and Koff=2.2*10-3.The interaction between SBP1 and the RBD of SARS-CoV-2 spike protein was validated by bio-layer interferometry. The KD, derived from protein association and dissociation kinetics, was found to be 47 nM after averaging the fitting values at different protein concentrations. The amino acid sequence of SBP1 is entirely derived from human ACE2 and should be recognized as endogenous by the human immune system. This feature could be highly beneficial in later stages of pre-clinical development. |
|
DC31006 |
WP1122
Featured
WP-1122(WP 1122) is a candidate drug to treat SARS-COV-2(COVID-19) .2-DG completely prevented SARS-CoV–2 replication in Caco–2 cells. Glycolysis is a process by which cells convert glucose into energy and infected (host) cells are induced by viruses to dramatically increase their dependence on glycolysis. WP1122 is a prodrug of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo. |
1204310-73-5 |
DC31010 |
S-Hydroxychloroquine
Featured
S enantiomer of Hydroxychloroquine. Hydroxychloroquine is a potent drug for the COVID-19 trement. |
137433-24-0 |
DC31011 |
R-Hydroxychloroquine
Featured
R enantiomer of Hydroxychloroquine. Hydroxychloroquine is a potent drug for the COVID-19 trement. |
137433-23-9 |
DC39023 |
AT-511(Bemnifosbuvir free base)
Featured
AT-511, the free base form of AT-527, against several coronaviruses, including SARS-CoV-2, the causative agent of COVID-19. In normal human airway epithelial (HAE) cell preparations, the average concentration of AT-511 required to inhibit replication of S |
1998705-64-8 |
DC39024 |
AT-527(Bemnifosbuvir hemisulfate)
Featured
AT-527(Bemnifosbuvir hemisulfate), a hemisulfate salt of AT-511, a guanosine nucleotide prodrug, is a potent and orally active HCV viral replication inhibitor. AT-527 is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir hemisulfate has pangenotypic antiviral activity[1][2][3].Bemnifosbuvir hemisulfate has pan-genotypic antiviral activities that inhibits HCV genotype 1a (HCV GT1a), HCV GT1b, HCV GT2a, HCV GT3a, HCV GT4a, and HCV GT5a replication with EC50 values of 12.8 nM, 12.5 nM, 9.2 nM, 10.3 nM, 14.7 nM, and 28.5 nM, respectively[1]. In normal human airway epithelial cells, the concentration of Bemnifosbuvir hemisulfate required to inhibit replication of SARS-CoV-2 by EC90 is 0.47 μM, very similar to its EC90 against HCoV-229E, HCoV-OC43 and SARS-CoV in Huh-7 cells[2].When given orally to rats (500 mg/kg) and monkeys (30 mg/kg, 100 mg/kg or 300 mg/kg), Bemnifosbuvir hemisulfate preferentially delivers high levels of AT-9010 in the liver in vivo[1]. |
2241337-84-6 |
DC39025 |
FOY-251
Featured
FOY 251 is a metabolite of Camostat and a pollen protease inhibitor for prevention and control of allergy. |
71079-08-8 |
DC50008 |
Colchicine
Featured
Colchicine is a potent therapeutic tool against COVID-19. Colchicine is a tricyclic alkaloid that is extracted from the plant Colchicum autumnale. Colchicine acts as a potent inhibitor of tubulin polymerization. |
64-86-8 |
DC50030 |
GRL-1720
Featured
GRL-1720 is an irreversible, covalent inhibitor of SARS-CoV-2 main protease (Mpro) with EC50 of 15 µM. |
|
DC50035 |
PF00835231
Featured
PF00835231(SARS-CoV-2 inhibitor 5h) is areversible-covalent inhibitor of SARS-CoV-2 main protease (Mpro) with EC50 of 4.2 µM. Compound 5h blocks the infectivity and cytopathicity of the virus with high potency and without any detectable cytotoxicity even at 200 µM.PF-00835231 is a potent inhibitor of CoV-2 3CLpro with IC50 of 4 nM and shows suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19. |
870153-29-0 |